There is one clinical trial.
The study aims to evaluate MN-166 (ibudilast) in patients with COVID-19 who are at risk of developing acute respiratory distress syndrome. Subjects will be screened, randomly assigned to MN-166 or placebo groups, receive study drug on Days 1-7, and followed up on Day 14 and Day 28.
Description: Proportion of subjects free from respiratory failure as defined by the need for decreased oxygen requirements (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at Day 7
Measure: Proportion of subjects free from respiratory failure Time: 7 daysDescription: Mean change from baseline in clinical status based on the NIAID 8-point scale (1= death, 8= not hospitalized, no limitations on activities) at Day 7. A higher score indicates improvement.
Measure: Mean change from baseline in clinical status using the NIAID 8-point ordinal scale at Day 7 Time: 7 daysDescription: Percentage of patients with at least a one-point improvement in clinical status using the NIAID 8-point ordinal scale (1= death, 8= not hospitalized, no limitations on activities) at Day 7. A higher score indicates improvement.
Measure: Percentage of patients with improvement in clinical status Time: 7 daysDescription: Mean change from baseline (baseline = 1-fold; any value above 1.0 indicates elevation in cytokine levels; any value below 1.0 indicates reduction in cytokine levels) in migration inhibitory factor (MIF), (interleukin 1-beta (IL-1β), interleukin 6 (IL-6), tumor necrosis factor (TNF-α), and C-reactive protein (CRP) at Day 7.
Measure: Change in cytokine levels from baseline Time: 7 daysDescription: Incidence, frequency, and severity of adverse events at Day 7 and Day 14
Measure: Adverse event Incidence, severity, relationship to study drug, and study discontinuations Time: Days 7, 14Description: Incidence of out-of-normal-range values and markedly abnormal change from baseline in laboratory safety test variables by treatment group.
Measure: Changes in laboratory values from baseline Time: 7 daysDescription: Proportion of subjects free from respiratory failure as defined by the need for decreased oxygen requirement (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at Day 14
Measure: Proportion of subjects free from respiratory failure as defined by the need for decreased oxygen requirement (invasive mechanical ventilation, non-invasive ventilation, high-flow oxygen, or ECMO, CPAP, BiPAP, nasal cannula) at Day 14 Time: 14 daysDescription: Mean change from baseline in clinical status using the NIAID 8-point ordinal scale at Day 14 and Day 28
Measure: Mean change from baseline in clinical status Time: Days 14, 28Description: Proportion of subjects receiving mechanical ventilation or intubation.
Measure: Incidence of mechanical ventilation or intubation Time: Days 7, 14Description: Proportion of subjects requiring submission to the intensive care unit
Measure: Intensive care unit admission Time: 7 daysDescription: Blood sample collection to determine plasma concentrations of ibudilast.
Measure: Plasma concentrations of Ibudilast Time: 7 daysDescription: Number of deaths from any cause
Measure: All cause mortality Time: Days 7, 14, 28